Drugs /

mgc018

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC) comprised of an anti-B7-homolog 3 (B7-H3, CD276) humanized immunoglobulin G1 (IgG1)/kappa monoclonal antibody conjugated through reduced interchain disulfides to the cleavable linker-duocarmycin payload, valine-citrulline-seco DUocarmycin hydroxyBenzamide Azaindole (vc-seco-DUBA), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-B7-H3 ADC MGC018 specifically targets and binds to the cell surface antigen B7-H3, leading to internalization of the ADC by the tumor cell. The linker is cleaved inside the tumor cell by proteases at the dipeptide valine-citrulline (vc), thereby releasing the duocarmycin payload. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.

Clinical Trials

View Clinical Trials for mgc018

Mgc018 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mgc018, 1 is phase 1/phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for mgc018 clinical trials.

Breast carcinoma, head and neck squamous cell carcinoma, and melanoma are the most common diseases being investigated in mgc018 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mgc018
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mgc018 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mgc 018, mg-c018, anti-b7h3 adc, anti-b7h3 antibody-drug conjugate mgc018
Drug Target(s) [2]:
CD276
NCIT ID [1]:
C159495

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.